Affinage

BEX2

Protein BEX2 · UniProt Q9BXY8

Length
128 aa
Mass
15.3 kDa
Annotated
2026-06-09
29 papers in source corpus 21 papers cited in narrative 21 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

BEX2 is a small adaptor-type protein that integrates transcriptional, apoptotic, autophagic, and signaling programs in cancer cells, with a context-dependent role that spans tumor-suppressive and tumor-promoting functions (PMID:16314316, PMID:19711341, PMID:33299012). In the nucleus, it acts as a transcriptional co-activator, joining an LMO2–NSCL2–LDB1 DNA-binding complex and enhancing LMO2- and NSCL2-dependent transcription (PMID:16314316), and it interacts with the SWI/SNF subunit INI1/hSNF5 to drive S-phase entry (PMID:22698742). BEX2 sits within reciprocal transcriptional feedback loops: its promoter is directly bound and activated by c-Jun and NF-κB p65, and in turn BEX2 is required for p65/IκBα and c-Jun phosphorylation, JNK activity, and c-Jun-driven cyclin D1 induction and ErbB2 expression (PMID:20482821, PMID:21384344, PMID:28367093), with nuclear localization being required for its promotion of p65 (PMID:24390962). BEX2 controls mitochondrial apoptosis by upregulating Bcl-2 and repressing BAD, BAK1, and PUMA, governs G1 progression through cyclin D1 and p21, and restrains PP2A activity (PMID:19711341). It promotes autophagy and mitophagy through multiple routes: lysine-59 crotonylation enables crotonylated BEX2 to bridge the NDP52–LC3B interaction (PMID:37777549), it inhibits PI3K by displacing the PIK3CA–p85 interaction to activate autophagic flux via PI3K/AKT/mTOR (PMID:41398291), and it acts through the BNIP3/NIX pathway in neuronal cells (PMID:34673406). BEX2 also suppresses mitochondrial oxygen consumption through interaction with TUFM (PMID:33299012), promotes MCL1 ubiquitination and degradation (PMID:41814669), and restrains Hedgehog signaling by retaining Zic2 in the cytoplasm (PMID:31929751). Its expression is governed by promoter methylation and histone deacetylation (PMID:16818640, PMID:19835597) and it escapes X-chromosome inactivation (PMID:33244819).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 2005 High

    Established BEX2 as a nuclear transcriptional co-activator by placing it within a defined DNA-binding complex, answering what molecular role this otherwise uncharacterized protein plays.

    Evidence GST pull-down, Co-IP, EMSA, and reporter assays identifying an LMO2–NSCL2–LDB1 complex

    PMID:16314316

    Open questions at the time
    • No structure of the complex or DNA-binding element defined
    • Does not address BEX2's cytoplasmic functions
  2. 2006 Medium

    Showed BEX2 can act as an epigenetically silenced tumor suppressor, addressing whether its loss contributes to cancer.

    Evidence Promoter methylation analysis, pharmacologic reactivation, viral re-expression, and xenografts in glioma

    PMID:16818640

    Open questions at the time
    • Mechanism of tumor suppression not resolved
    • Apparent contradiction with later pro-proliferative roles unexplained
  3. 2007 Medium

    Connected BEX2 to apoptosis regulation by defining an NGF/BEX2/NF-κB anti-apoptotic axis in breast cancer.

    Evidence siRNA knockdown, overexpression, NF-κB reporter and apoptosis assays

    PMID:17638883

    Open questions at the time
    • Direct molecular link between BEX2 and NF-κB not defined
    • Mechanism upstream of NF-κB activation unclear
  4. 2009 Medium

    Placed BEX2 genetically downstream of MLL fusion proteins and reinforced epigenetic control of its expression.

    Evidence MS-MLPA methylation analysis, demethylating agents/HDAC inhibitors, MLL-ENL transgenic cell lines

    PMID:19835597

    Open questions at the time
    • Direct transcriptional regulation by MLL fusions not shown
    • Functional role of BEX2 in AML not tested
  5. 2010 Medium

    Defined the apoptotic and cell-cycle effector mechanism of BEX2 through Bcl-2 family modulation, cyclin D1/p21, and PP2A.

    Evidence Reciprocal knockdown/overexpression with Bcl-2 family and PP2A activity readouts in breast cancer cells

    PMID:19711341

    Open questions at the time
    • Whether BEX2 directly binds Bcl-2 members or acts transcriptionally not resolved
    • PP2A regulation mechanism unknown
  6. 2010 Medium

    Established a transcriptional feedback loop in which c-Jun and p65 drive BEX2, which in turn sustains NF-κB and JNK/c-Jun activity, explaining its self-reinforcing pro-proliferative role.

    Evidence ChIP, luciferase reporter, and phosphorylation Western blots in c-Jun stable lines

    PMID:20482821

    Open questions at the time
    • Molecular mechanism by which BEX2 promotes kinase phosphorylation not defined
  7. 2011 Medium

    Extended the feedback circuit to ErbB2, showing a positive ErbB2–c-Jun–BEX2 loop in breast cancer.

    Evidence ErbB2 overexpression, dominant-negative c-Jun, ChIP, promoter assays

    PMID:21384344

    Open questions at the time
    • Direct BEX2 contribution to ErbB2 promoter occupancy not separated from c-Jun
  8. 2012 Medium

    Identified BEX2 as an upstream regulator of JNK-mediated glioma cell survival and migration, broadening its role beyond breast cancer.

    Evidence siRNA/overexpression with SP600125 epistasis, migration/invasion assays, N-cadherin and MMP-2 readouts

    PMID:22907646 PMID:23022184

    Open questions at the time
    • Direct JNK pathway target of BEX2 unknown
    • Migration findings of lower confidence
  9. 2012 Medium

    Identified a physical interaction with the SWI/SNF subunit INI1/hSNF5, providing a chromatin-remodeling route to BEX2 cell-cycle control.

    Evidence Yeast two-hybrid, GST pull-down, truncation mapping, co-localization, cell cycle analysis

    PMID:22698742

    Open questions at the time
    • Functional consequence for SWI/SNF activity not defined
    • Target genes affected unknown
  10. 2014 Medium

    Demonstrated that BEX2 nuclear localization is required for its NF-κB-dependent proliferative function and that it acts via β-catenin in glioma invasion.

    Evidence NLS-deletion mutant, p65 co-knockdown epistasis, β-catenin rescue, proliferation/migration assays

    PMID:24390962 PMID:25490384

    Open questions at the time
    • How BEX2 raises p65 levels mechanistically unclear
    • β-catenin link is indirect, no binding shown
  11. 2017 Medium

    Confirmed BEX2 as an upstream activator of JNK/c-Jun signaling driving proliferation in colorectal cancer and as a mediator of induced autophagy in neurons.

    Evidence Knockdown/overexpression with SP600125 epistasis and xenografts; isoflavone-induced LC3-II/p62 autophagy in SH-SY5Y cells

    PMID:28367093 PMID:29049987

    Open questions at the time
    • Direct kinase substrate or adaptor function not defined
    • Autophagy role established only by knockdown phenotype
  12. 2020 Medium

    Revealed BEX2's mitochondrial and Hedgehog-suppressive functions, identifying TUFM, FEM1B/CUL2, and cytoplasmic Zic2 retention as new mechanistic nodes.

    Evidence Protein binding screen, Co-IP, oxygen consumption, CRISPR knockout with Hedgehog inhibitor and Zic2 epistasis, metastasis models

    PMID:31929751 PMID:33299012

    Open questions at the time
    • Functional role of FEM1B/CUL2 interaction unresolved
    • Mechanism of Zic2 cytoplasmic retention not defined
  13. 2020 Medium

    Showed BEX2 escapes X-chromosome inactivation, establishing biallelic dosage potential.

    Evidence Allele-specific expression in patient-derived iPSCs with Xq22 deletion

    PMID:33244819

    Open questions at the time
    • Single patient/case
    • Functional consequence of escape not tested
  14. 2023 Medium

    Identified lysine-59 crotonylation as the modification that enables BEX2 to bridge NDP52 and LC3B for mitophagy and chemoresistance.

    Evidence K59R mutagenesis, Co-IP, mitophagy and apoptosis assays, xenografts in lung cancer

    PMID:37777549

    Open questions at the time
    • Crotonyltransferase responsible for K59 modification not identified
    • Structural basis of NDP52–LC3B bridging unknown
  15. 2025 Medium

    Established BEX2 as a direct PI3K inhibitor that disrupts the PIK3CA–p85 interaction to promote autophagy via PI3K/AKT/mTOR.

    Evidence Co-IP, confocal microscopy, rapamycin treatment in NSCLC cells

    PMID:41398291

    Open questions at the time
    • Binding interface on PIK3CA not mapped
    • Relationship to crotonylation-dependent mitophagy unresolved
  16. 2026 Medium

    Defined BEX2 as a promoter of MCL1 ubiquitination and degradation, linking its loss to cancer stem cell stemness and Hedgehog activity.

    Evidence Co-IP, ubiquitination assay, sphere formation/ELDA, xenografts in colorectal cancer

    PMID:41814669

    Open questions at the time
    • E3 ligase recruited by BEX2 for MCL1 not identified
    • Connection to FEM1B/CUL2 interaction not tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How BEX2's diverse nuclear (transcriptional co-activation, SWI/SNF) and cytoplasmic/mitochondrial (PI3K inhibition, mitophagy, MCL1 degradation, TUFM) activities are coordinated, and whether its context-dependent tumor-suppressor versus oncogenic behavior reflects distinct PTM states or partner availability, remains unresolved.
  • No unifying structural or biochemical model integrating BEX2's many partners
  • Determinants of tumor-suppressive versus pro-tumor outcomes undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 3 GO:0098772 molecular function regulator activity 3 GO:0140110 transcription regulator activity 1
Localization
GO:0005634 nucleus 3 GO:0005739 mitochondrion 3 GO:0005829 cytosol 2
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-9612973 Autophagy 3 R-HSA-1640170 Cell Cycle 2 R-HSA-5357801 Programmed Cell Death 2 R-HSA-74160 Gene expression (Transcription) 2
Partners
CUL2FEM1BLDB1LMO2MCL1PIK3CASMARCB1TUFM
Complex memberships
LMO2–NSCL2–LDB1 transcriptional complex

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2005 BEX2 physically interacts with LMO2 (a LIM-domain transcription factor), confirmed by GST pull-down and co-immunoprecipitation. BEX2 and LMO2 form part of a DNA-binding protein complex (shown by EMSA) that also includes NSCL2 and LDB1, and BEX2 enhances the transcriptional activity of LMO2 and augments LMO2-induced NSCL2-dependent transcriptional activity in vivo. GST pull-down, co-immunoprecipitation, EMSA, luciferase reporter assay, mammalian two-hybrid Nucleic acids research High 16314316
2006 BEX2 promoter is hypermethylated and transcriptionally silenced in malignant glioma. Viral re-expression of BEX2 increases sensitivity to chemotherapy-induced apoptosis and exerts tumor suppressor effects in vitro and in a xenograft mouse model. 5-AzaC/TSA pharmacologic reversal, microarray, promoter methylation analysis, viral transduction, xenograft model Cancer research Medium 16818640
2007 BEX2 expression is necessary and sufficient for NGF-mediated inhibition of ceramide-induced apoptosis through NF-κB activation in breast cancer cells. BEX2 also modulates apoptosis in response to estradiol and tamoxifen, defining a NGF/BEX2/NF-κB pathway. siRNA knockdown, BEX2 overexpression, NF-κB reporter assay, apoptosis assay Cancer research Medium 17638883
2009 BEX2 expression (hypomethylated) is characteristic of MLL-translocation AML cell lines; demethylating agents and HDAC inhibitors restore BEX2 expression in MLLwt cells. Bex2 mRNA in MLL-ENL transgenic mouse cell lines requires expression of the MLL fusion gene, placing BEX2 downstream of MLL fusion proteins. MS-MLPA methylation analysis, demethylating agent treatment, transgenic mouse cell lines Molecular cancer Medium 19835597
2010 BEX2 downregulation induces mitochondrial apoptosis and sensitizes breast cancer cells to ceramide, doxorubicin, and staurosporine. BEX2 overexpression protects against mitochondrial apoptosis. This effect is mediated through positive regulation of Bcl-2 and negative regulation of BAD, BAK1, and PUMA. BEX2 expression is also required for normal G1 cell cycle progression through regulation of cyclin D1 and p21. BEX2 downregulation increases protein phosphatase 2A (PP2A) expression and activity. siRNA knockdown, BEX2 overexpression, apoptosis assay, Western blot for Bcl-2 family members, cell cycle analysis, PP2A activity assay International journal of cancer Medium 19711341
2010 c-Jun and p65/RelA directly bind and transcriptionally activate the BEX2 promoter in breast cancer cells. In turn, BEX2 is required for normal phosphorylation of p65 and IκBα (NF-κB activation), for phosphorylation of c-Jun, and for JNK kinase activity, establishing a feedback loop. BEX2 is also required for c-Jun-mediated cyclin D1 induction and cell proliferation. BEX2 downregulation increases PP2A activity in c-Jun stable lines. Luciferase reporter assay, chromatin immunoprecipitation (ChIP), Western blot, c-Jun stable lines, PP2A activity assay Molecular cancer Medium 20482821
2011 ErbB2 overexpression induces c-Jun and BEX2 expression; ErbB2-mediated BEX2 induction is abrogated by a dominant-negative c-Jun mutant. BEX2 overexpression in turn increases c-Jun-mediated ErbB2 induction and c-Jun binding to the ErbB2 promoter, establishing a positive feedback loop among ErbB2, c-Jun, and BEX2 in breast cancer cells. ErbB2 overexpression, dominant-negative c-Jun mutant, Western blot, ChIP, promoter assay International journal of cancer Medium 21384344
2012 BEX2 downregulation inhibits glioma cell migration and invasion, associated with increased N-cadherin and decreased secretion of MMP-2; BEX2 overexpression promotes migration and invasion, placing BEX2 upstream of N-cadherin and MMP-2 in glioma. siRNA knockdown, overexpression, migration/invasion assays, Western blot, zymography Journal of molecular neuroscience Low 22907646
2012 BEX2 downregulation promotes apoptosis and activates the JNK pathway in malignant glioma cells; the JNK-specific inhibitor SP600125 abolishes the pro-apoptotic effect of BEX2 knockdown, placing BEX2 upstream of JNK in glioma cell survival. siRNA knockdown, BEX2 overexpression, JNK inhibitor (SP600125), apoptosis assay Biochemical and biophysical research communications Medium 23022184
2012 BEX2 interacts with INI1/hSNF5 (a SWI/SNF chromatin remodeling complex component), confirmed by yeast two-hybrid and GST pull-down; truncated mutation analysis identified that two conserved reverse repeat sequences in INI1/hSNF5 are required for this interaction. Both proteins co-localize in the nucleus, and co-overexpression increases S-phase population, indicating BEX2 regulates cell cycle via INI1/hSNF5. Yeast two-hybrid, GST pull-down, truncated mutation analysis, subcellular localization, cell cycle analysis Yi chuan = Hereditas Medium 22698742
2014 BEX2 promotes proliferation of glioblastoma cells through NF-κB signaling: BEX2 downregulation decreases NF-κB p65 expression; BEX2 overexpression-induced proliferation is abolished by p65 downregulation. Critically, BEX2 with a nuclear localization signal deletion no longer promotes p65 expression, demonstrating that BEX2 nuclear localization is required for this function. siRNA knockdown, overexpression, nuclear localization signal deletion mutant, proliferation assay, Western blot Journal of molecular neuroscience Medium 24390962
2014 BEX2 downregulation inhibits glioma cell migration and invasion by reducing β-catenin protein levels (nuclear and cytoplasmic, not membrane-associated); β-catenin overexpression rescues the migration/invasion defect caused by BEX2 knockdown, placing BEX2 upstream of β-catenin in glioma cell invasiveness. siRNA knockdown, β-catenin overexpression rescue, Western blot, migration/invasion assay Biochemical and biophysical research communications Low 25490384
2017 BEX2 promotes colorectal cancer cell proliferation via the JNK/c-Jun pathway: BEX2 knockdown inhibits JNK/c-Jun phosphorylation; BEX2 overexpression activates JNK/c-Jun phosphorylation; the JNK inhibitor SP600125 abolishes BEX2 overexpression-induced proliferation, establishing BEX2 as an upstream regulator of JNK/c-Jun signaling in colorectal cancer. siRNA knockdown, BEX2 overexpression, JNK inhibitor (SP600125) pharmacologic epistasis, phosphorylation Western blot, proliferation assay, xenograft model International journal of biological sciences Medium 28367093
2017 BEX2 is required for isoflavone-induced autophagy in SH-SY5Y neuronal cells: BEX2 siRNA abolishes isoflavone-mediated LC3-II accumulation, p62 decrease, and neuroprotection against atrazine toxicity, placing BEX2 as a necessary mediator of autophagy induction in these cells. siRNA knockdown, Western blot (LC3-II, p62), autophagy inhibitor (3-MA), cell viability assay Cellular physiology and biochemistry Low 29049987
2020 BEX2 knockdown in cholangiocarcinoma decreases tumorigenicity and G0 phase fraction. Starvation induces USF2 transcription factor, which transcriptionally induces BEX2. BEX2 binding partners identified include E3 ubiquitin ligase complex proteins FEM1B and CUL2 and mitochondrial protein TUFM; knockdown of BEX2 or TUFM increases mitochondrial oxygen consumption rate and decreases tumorigenicity, indicating BEX2 suppresses mitochondrial activity through TUFM interaction. Comprehensive protein binding screen, co-immunoprecipitation, siRNA knockdown, oxygen consumption assay, xenograft model, cell cycle analysis Scientific reports Medium 33299012
2020 BEX2 knockout in colorectal cancer cells activates the Hedgehog signaling pathway and promotes migration/metastasis; Hedgehog inhibitors (GANT61 and GDC-0449) rescue the migratory enhancement of BEX2-knockout cells. BEX2 negatively modulates Hedgehog signaling by retaining Zic2 in the cytoplasm; BEX2 loss causes nuclear translocation of Zic2, activating Hedgehog signaling, and Zic2 knockdown abrogates the migratory phenotype of BEX2-knockout cells. CRISPR/Cas9 knockout, RNA-Seq, Hedgehog inhibitor rescue, Zic2 knockdown epistasis, subcellular fractionation/localization, migration assay, in vivo metastasis model International journal of biological sciences Medium 31929751
2020 BEX2 escapes X-chromosome inactivation, demonstrated by biallelic BEX2 expression in iPSCs derived from a female patient with Xq22 deletion, in the iPSC line where the wild-type allele was inactivated. iPSC derivation from patient, allele-specific expression analysis Congenital anomalies Medium 33244819
2021 BEX2 activates mitophagy via the BNIP3/NIX pathway in SH-SY5Y neurons: BEX2 knockdown inhibits soybean isoflavone-induced BNIP3/NIX upregulation, LC3-II accumulation, and mitophagy, and prevents protection against atrazine-induced mitochondrial damage, placing BEX2 upstream of BNIP3/NIX-mediated mitophagy. siRNA knockdown, Western blot (BNIP3/NIX, LC3-II, BEX2), mitophagy inhibitor (Mdivi-1), mitochondrial membrane potential assay, electron microscopy Ecotoxicology and environmental safety Low 34673406
2023 BEX2 is crotonylated at lysine 59 (K59), and this crotonylation is critical for BEX2-mediated mitophagy in lung cancer cells. Crotonylated BEX2 facilitates interaction between NDP52 and LC3B to promote mitophagy; the K59R mutation of BEX2 impairs the NDP52-LC3B interaction and inhibits mitophagy, thereby reducing resistance to chemotherapy-induced apoptosis. Site-directed mutagenesis (K59R), co-immunoprecipitation, Western blot, mitophagy assay, apoptosis assay, in vivo xenograft model Cell death & disease Medium 37777549
2025 BEX2 interacts with PIK3CA (the catalytic subunit of PI3K) and impairs the PIK3CA–p85 (regulatory subunit) interaction, thereby inhibiting PI3K activity and promoting autophagic flux through the PI3K/AKT/mTOR signaling pathway in non-small-cell lung cancer cells. Co-immunoprecipitation, Western blot, confocal microscopy, rapamycin treatment Cell communication and signaling Medium 41398291
2026 BEX2 interacts with MCL1, promotes its ubiquitination and degradation, thereby reducing MCL1 stability. Low BEX2 expression stabilizes MCL1, which enhances cancer stem cell stemness potential and Hedgehog pathway activity in colorectal cancer cells. Co-immunoprecipitation, ubiquitination assay, Western blot, functional stem cell assays (sphere formation, ELDA), xenograft model Cancer biology & medicine Medium 41814669

Source papers

Stage 0 corpus · 29 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2006 Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer research 133 16818640
2007 BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer research 81 17638883
2009 Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia (New York, N.Y.) 58 19412433
2010 BEX2 regulates mitochondrial apoptosis and G1 cell cycle in breast cancer. International journal of cancer 47 19711341
2023 Crotonylated BEX2 interacts with NDP52 and enhances mitophagy to modulate chemotherapeutic agent-induced apoptosis in non-small-cell lung cancer cells. Cell death & disease 43 37777549
2005 Human Bex2 interacts with LMO2 and regulates the transcriptional activity of a novel DNA-binding complex. Nucleic acids research 35 16314316
2010 BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer. Molecular cancer 33 20482821
2020 BEX2 suppresses mitochondrial activity and is required for dormant cancer stem cell maintenance in intrahepatic cholangiocarcinoma. Scientific reports 28 33299012
2017 Isoflavones Induce BEX2-Dependent Autophagy to Prevent ATR-Induced Neurotoxicity in SH-SY5Y Cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 27 29049987
2009 Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia. Molecular cancer 27 19835597
2020 Silencing of brain-expressed X-linked 2 (BEX2) promotes colorectal cancer metastasis through the Hedgehog signaling pathway. International journal of biological sciences 26 31929751
2014 Bex2 controls proliferation of human glioblastoma cells through NF-κB signaling pathway. Journal of molecular neuroscience : MN 23 24390962
2012 Bex2 is critical for migration and invasion in malignant glioma cells. Journal of molecular neuroscience : MN 23 22907646
2012 Bex2 regulates cell proliferation and apoptosis in malignant glioma cells via the c-Jun NH2-terminal kinase pathway. Biochemical and biophysical research communications 23 23022184
2021 Soybean isoflavones protect SH-SY5Y neurons from atrazine-induced toxicity by activating mitophagy through stimulation of the BEX2/BNIP3/NIX pathway. Ecotoxicology and environmental safety 21 34673406
2022 Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling. Theranostics 20 36451866
2017 BEX2 promotes tumor proliferation in colorectal cancer. International journal of biological sciences 18 28367093
2021 BEX2 is required for maintaining dormant cancer stem cell in hepatocellular carcinoma. Cancer science 17 34424582
2019 Molecular functions of brain expressed X-linked 2 (BEX2) in malignancies. Experimental cell research 17 30779920
2014 Β-catenin is involved in Bex2 down-regulation induced glioma cell invasion/migration inhibition. Biochemical and biophysical research communications 15 25490384
2011 A feedback loop between BEX2 and ErbB2 mediated by c-Jun signaling in breast cancer. International journal of cancer 15 21384344
2019 MicroRNA-370 functions as a tumor suppressor in hepatocellular carcinoma via inhibition of the MAPK/JNK signaling pathway by targeting BEX2. Journal of human genetics 9 31530937
2021 Discovery of a chemical compound that suppresses expression of BEX2, a dormant cancer stem cell-related protein. Biochemical and biophysical research communications 7 33412384
2021 Analyzing differentially expressed genes and pathways of Bex2-deficient mouse lung via RNA-Seq. Turkish journal of biology = Turk biyoloji dergisi 4 34803456
2020 Induced pluripotent stem cells established from a female patient with Xq22 deletion confirm that BEX2 escapes from X-chromosome inactivation. Congenital anomalies 4 33244819
2012 [BEX2 regulates cell cycle through the interaction with INI1/hSNF5]. Yi chuan = Hereditas 4 22698742
2023 JNK/MAPK pathway regulation by BEX2 gene silencing in alcoholic hepatitis mice: Effects on oxidative stress. Alcohol, clinical & experimental research 2 37864534
2026 BEX2 influences the MCL1-Hedgehog signaling axis to regulate the potential of stemness characterization in colorectal cancer. Cancer biology & medicine 1 41814669
2025 BEX2 regulates autophagy by inhibiting PIK3CA-p85 interaction in non-small-cell lung cancer cells. Cell communication and signaling : CCS 1 41398291

Missed literature

Know a paper Affinage missed for BEX2? Flag it for the maintainers and the community.

No submissions yet.